Multiple Myeloma Patient Registry

Inclusion Criteria:

- Must sign, and/or their legally acceptable representative where applicable must sign,
a participation agreement/informed consent form (ICF) allowing data collection and
source data verification in accordance with local requirements

- Have a diagnosis of relapsed MM [according to 2014 International Myeloma Working Group
(IMWG) criteria] with 1 to 3 prior lines of therapy. (An induction regimen followed by
autologous stem cell transplantation and single-agent maintenance therapy will be
considered a single line of therapy.)

- Participants must have initiated a new line of induction therapy that includes a
proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) within 90 days prior to
enrollment. A short course of corticosteroids is allowed prior to initiating the new
line of induction therapy

- Must be willing and able to complete the protocol-required patient-reported outcome
(PROs)

Exclusion Criteria:

- Participant has plasma cell leukemia [greater than (>) 2.0 * 10^9 per liter]
circulating plasma cells by standard differential), Waldenstrom's macroglobulinemia,
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and/or skin
changes), or amyloid light-chain amyloidosis

- Participant has a life expectancy of less than 6 months

- At the time of screening, participant is enrolled in an interventional clinical trial
for MM using an anti-neoplastic agent that is not currently approved by the United
States (US) Food and Drug Administration (FDA)